Poxel : Poxel holds all the cards
>A little more visibility for Imeglimin in Europe and the US - As we expected, Poxel will officially recover Imeglimin's rights in the US and Europe from 31 January 2021. As announced at the end of 2020, Metavant, a subsidiary of Roivant, has decided to withdraw from the future phase III. This decision, motivated by strategic considerations specific to Roivant ("the holding company that owns Metavant") which seems to want to get out of diabetes, does not in any way co...Poxel is a clinical-stage biopharmaceutical company focused on the development of treatments for type 2 diabetes and metabolic disease. Co.'s two drug candidates, Imeglimin and PXL770, are intended to complement and augment existing type 2 diabetes therapies, including in patients who no longer fully respond to such therapies, with the goal of helping patients better control their type 2 diabetes and reduce potentially disabling or fatal complications.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.